United States
Inmedix Inc is a biotechnology and healthcare startup based in the United States, founded in 2017. The company's goal is to bring accurate and safe heart rate variability (HRV) diagnostic services to clinicians by applying HRV on a high-fidelity ECG platform with cloud-based analysis and reporting. Currently, Inmedix is focused on the FDA submission and clearance processes, and they are committed to sharing reviewed information only after clearance, demonstrating their respect for FDA concerns.
The last investment received by Inmedix was a $3.05M Seed Round investment on 30 December 2022. The investors involved in this round are not specified.
With its focus on cutting-edge medical technology and adherence to regulatory standards, Inmedix presents an intriguing investment opportunity for venture capitalists looking to support the advancement of diagnostic tools in the healthcare industry. The potential impact of their innovative approach coupled with their dedication to FDA compliance makes them an attractive prospect for investors seeking to contribute to the future of healthcare.
